MaRS client Profound Medical closes Canada’s largest early-stage medical device venture capital financing in recent years
Summary
“We’re absolutely delighted to have secured such a significant sum of financing and in such an unbelievably tough financial climate,” says Paul Chipperton, CEO of Profound Medical. By delivering the treatment in a less invasive way and by using the latest imaging technology, Profound is well positioned to improve patient outcome,” says Jean-François Pariseau, Partner of BDC Health Venture Fund, who will soon join the company’s Board of Directors. “As a client company of MaRS, we’ve been very grateful for its help and continued support in what is simply the hardest and most challenging technology financing environment any of us have lived through,” says Chipperton. Through its expertise and network, Genesys accelerates the development of commercially viable emerging companies that represent promising life science investment opportunities. MaRS works closely with entrepreneurs to grow and scale their ventures into global market leaders in life sciences and health care, information, communications and entertainment technologies, cleantech, advanced materials and engineering, as well as innovative social purpose businesses.